May 31, 2021 / 03:00AM GMT
Operator
Ladies and gentlemen, good day, and welcome to Q4 FY '21 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I would now like to hand the conference over to Mr. Ravi Agrawal. Thank you, and over to you, sir.
Ravi Agrawal - Glenmark Pharmaceuticals Limited - IR Officer
Yes. Thank you, moderator. Good morning, everyone, and a warm welcome to the Q4 FY '21 Results Conference Call of Glenmark Pharmaceuticals Limited.
Before we start the call, a review of the operations of the company. For the fourth quarter of FY 2021, Glenmark's consolidated revenue was at INR 28,599 million, recording an increase of 3.3% year-on-year. For the year ending March 31, 2021, Glenmark's consolidated revenue was at INR 109,439 million, recording an increase of 2.8% year-on-year.
Our corporate announcement. Glenmark Life Sciences Limited has filed a DRHP with the Securities and Exchange Board of India for a proposed IPO comprising a fresh issue of up to INR 11,600 million and
Full Year 2021 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
May 31, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers